15 Posts Not To Miss from APCCC24!
The Advanced Prostate Cancer Consensus Conference 2024 (APCCC24) was held from April 25th to April 27th in Lugano, Switzerland. Our team at OncoDaily has selected 15 posts not to miss from this event!
Celebrating the 10th anniversary of the PEACE consortium, a European Prostate Cancer Research Group. 10 years, 10 phase III randomized trials… huge impact on patients, led by Profesor Karim Fizazi. Congrats!
What is the role of digital rectal exam (DRE)? No role in primary care, no role in early detection by urologist if MRI available, some role in local staging of prostate cancer by urologist. Excellent talk by Declan Murphy.
Well said by Dr. David Matheson, himself a prostate cancer patient. ‘There is no good cancer. Thanks for starting the meeting with the patient perspective.
As a patient, I was honestly incensed that a quarter of the “expert” panel would not even DISCUSS let alone recommend intermittent ADT with their patient. That’s disgraceful. We have a long way to go to achieve patient centric medicine.
Compelling argument by Alberto Briganti on using surgery for management of high-risk prostate cancer and how this can actually de-intensify treatment for some patients.
At APCCC19, we asked whether you should be doing PSMA PET/CT. In 2024, many questions presume you have done a PSMA PET/CT to make a decision. Big progress in 5 years!
Very honored to attend APCCC24 meeting with international KOL on prostate cancer and now to enjoy the italian swiss food together.
Key takeaways from Stacy Loeb on social media and AI use:
- holds great promise for LMICs
- need to ensure accuracy, comprehensibility and equity
- good access to devices exists
- studies show clinical benefits
- can scale at low cost
- representation important
Great comments by Daniel E Spratt on PSMA therapy:
- Should be treated as radiation treatment and not drug
- Activity (not dose) should be adapted to tumor burden to ensure proper efficacy
- Impact of fractionation needs to be studied
This is excellent conference. But it is not lost on this patient that the session focusing on disparities and the explosion of PC in Africa and Asia is the ONLY panel that has Black doctors presenting. And at the end of the day with a half empty room. We can do better.
Excellent talk on germline testing in PC by Heather H. Cheng. It matters for patients AND families. Germline alterations are FREQUENT and have consequences for patients. Tumor-only sequencing failed to detect > 20% of pathogenic variants
María Natalia Gandur Quiroga (Argentina)
APCCC24 Day 3 Highlights!
- Heather Cheng – Urgency of germline testing in advanced prostate cancer. Detect mutations to open personalized treatment options.
-
Ana Aparicio – Impact of non-DDR genomic alterations on the management of prostate cancer. Highlights the importance of biomarkers for FDA-approved targeted drugs.
-
Misha Beltran – Differentiating aggressive variants of castration-resistant prostate cancer. It highlights the need for combined strategies to address diseases caused and not caused by RA.
-
Andrew Armstrong – Discusses treatment for neuroendocrine and aggressive variants, highlighting platinum combinations and the need for genomic testing for targeted therapies.
- Matthew Smith – Challenges in sequencing chemotherapy and PSMA radioligand therapy. Discusses the potential superiority of 177Lu-PSMA-617.
-
Michael Hofman – Comparison of alternative PSMA ligands for diagnosis and treatment. The equivalence between 68Ga-PSMA-11 and 18F-DCFPyL is discussed.
-
Stefano Fanti – Use of CT findings in PSMA PET/CT. Discusses the challenges with false positives and the importance of acting on high PSMA PET detection rates.
Each presentation highlights the crucial need for genomic evaluation and personalized therapy in the treatment of prostate cancer.
95% of APCCC Lugano Panelists DO NOT recommend ARPI switch for mCRPC. Yet why do investigators (many of them Panelists) and FDA approve this as control arm for trials?
‘Unethical’, says Anthony M Joshua, from the floor, as did Vinay Prasad on GU Cast.
When Oligometastatix (aka me) and Pelvix (aka Vedang Murthy) share a 3 hour train ride home from APCCC24 , new trials are born! Be ready for us APCCC30!
Thanks again, Silke Gillessen and Aurelius Omlin for having us.
A heartfelt thank you to Silke, Aurelius, and all the APCCC staff for organizing such an excellent meeting. Your commitment to excellence shone through, making the event not only successful but also memorable. Your hard work and dedication to every detail truly made a difference!
